(Q37761045)

22 August 2017

1 reference

title

Use of vitamin D in chronic kidney disease patients (English)

1 reference

chronic renal insufficiency

22 August 2017

0 references

0 references

1 reference

Anca Gal-Moscovici

1

1 reference

PubMed ID

20505658

22 August 2017

Stuart M Sprague

series ordinal

2

1 reference

PubMed ID

20505658

22 August 2017

language of work or name

English

0 references

publication date

26 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

78

1 reference

22 August 2017

2

1 reference

22 August 2017

146-151

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2010.113

22 August 2017

0 references

cites work

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Mortality risk among hemodialysis patients receiving different vitamin D analogs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Effect of parathyroid hormone on erythropoiesis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

https://api.crossref.org/works/10.1038%2FKI.2010.113

1 reference

7 January 2021

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

1,25-Dihydroxyvitamin D3decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

High-density lipoprotein regulates calcification of vascular cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Bone morphogenetic protein expression in human atherosclerotic lesions.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

1,25-dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

On the evolving nature of understanding dialysis-related disorders

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Meta-analysis: vitamin D compounds in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Vitamin D levels and early mortality among incident hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Vitamin D affects survival independently of vascular calcification in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Chronic kidney disease, hypovitaminosis D, and mortality in the United States

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Association of oral calcitriol with improved survival in nondialyzed CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Association of activated vitamin D treatment and mortality in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Metabolites of vitamin D in human vitamin-D deficiency: effect of vitamin D3 or 1,25-dihydroxycholecalciferol

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Vitamin D, glucose tolerance and insulinaemia in elderly men

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Vitamin D analogues for the management of secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Regulation of gp330/megalin expression by vitamins A and D

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Low dose calcitriol versus placebo in patients with predialysis chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.113

7 January 2021

Identifiers

DOI

10.1038/KI.2010.113

1 reference

22 August 2017

1 reference

PubMed ID

20505658